scan

Reimagine the journey

Discover our pipeline and how we are approaching and developing innovative world-class radiopharmaceutical imaging solutions…

ImaginAb exist to challenge, create and to transform. We align this vision through every aspect of our strategy from development to market authorization and feedback.

Everything we do is focused on reimagining a new world of healthcare potential, optimising the immuno oncology patient care path and delivering greater insight to physicians and comfort to patients.

Our development process is precise and prompt. We partner with global pharmaceutical leaders and world-class clinicians to develop, trial and bring our innovative products to market.

Tomorrow’s cancer treatments begin here…discover our pipeline of biotech innovations.

PET Imaging

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
PET imaging of CD8 Cells in Oncology (89Zr-Df-Crefmirlimab)
 
 
 
 
 
PET imaging CD8 T-cells in Inclusion Body Myositis (89Zr-Df-Crefmirlimab)
 
 
 
 
 
PET Imaging CD4 T-cells trafficking in Oncology and Autoimmune diseases (89Zr-Df-IAB41M2C)
 
 
 
 
 

Optical Imaging

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
PSMA optical imaging: Prostate Cancer (IR800-IAB2MA)
 
 
 
 
 
PSMA optical imaging: Renal Cancer (IR800-IAB2MA)
 
 
 
 
 

Learn more about our Clinical Trials

    Unknown
    50+ years
    Male or Female
    NCT04874818

    CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

    Netherlands
    • Radboud University Medical Center
    A subset of patients diagnosed with severe acute respiratory syndrome (SARS)-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced cluster of differentiation (CD)8+ T-cell numbers, is correlated with clinical deterioration and intensive care unit (ICU) admission. The underlying reasons for lymphopenia in coronavirus disease (COVID)-19 is currently unclear, We aim to assess differences in the in vivo distribution of CD8+ T-cells in patients with proven SARS-CoV2 presenting with lymphopenia or with normal lymphocyte counts, using Zirconium-89 ([89Zr])Df-IAB22M2C positron emission tomography (PET) imaging.
    Recruiting
    18+ years
    Male or Female
    NCT06650163

    Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

    Northern America
    • UCLA / Jonsson Comprehensive Cancer Center
    This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presence and change in CD8 positive (+) tumor infiltrating lymphocytes (TIL) cells. Identifying the presence and changes in CD8+ cells can be challenging, particularly for participants with central nervous system (CNS) tumors, and usually requires invasive procedures such as repeat tissue biopsies, which may not accurately represent the immune status of the entire tumor. Zr-89 crefmirlimab berdoxam is known as a radioimmunoconjugate which consists of a radiolabeled anti-CD8+ minibody whose uptake can be imaged with PET. Upon administration, Zr 89 crefmirlimab berdoxam specifically targets and binds to the CD8+ cells. This enables PET imaging and may detect CD8+ T-cell distribution and activity and may help determine the patient's response to cancer immunotherapeutic agents more accurately. Giving Zr-89 crefmirlimab berdoxam along with undergoing immuno-PET imaging may work better at identifying immune cell activity in patients with resectable brain tumors.
    Recruiting
    18+ years
    Male or Female
    CT05371132

    Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

    Northern America
    • City of Hope National Medical Center
    "This phase I trial investigates the effect of radiation therapy on the immune system, specifically CD8 positive (+) T cells, in lymphoma patients receiving bridging radiation therapy before CAR T-cell infusion, and metastatic patients with solid tumor malignancies receiving SBRT. CD8+ T cells are mainly found in lymph tissue and play a significant role in anti-tumor immunity. These cells can infiltrate tumor cells and kill them. Radiation therapy may recruit CD8 T cells and this recruitment may help with tumor control. Diagnostic procedures, such as zirconium Zr 89-Df-crefmirlimab positron emission tomography (PET), may be a less invasive way to check and monitor for CD8+ T cells before and after radiation therapy."

Join us to reimagine the future of immuno oncology.